All In MedTech

FDA Clearance Tracker · P050053

INFUSE BONE GRAFT

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Mar 9, 2007 (this decision)Source: openFDAMethods & limitations

PMA

The decision

FDA number
P050053
Device name
INFUSE BONE GRAFT
Applicant location
Memphis, TN
Received
Dec 30, 2005
Decided
Mar 9, 2007
Decision
Approved
Supplements
63 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 872.3930

Every decision under product code NPZ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE INFUSE BONE GRAFT. THE DEVICE IS INDICATED AS AN ALTERNATIVE TO AUTOGENOUS BONE GRAFT FOR SINUS AUGMENTATIONS, AND FOR LOCALIZED ALVEOLAR RIDGE AUGMENTATIONS FOR DEFECTS ASSOCIATED WITH EXTRACTION SOCKETS.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NPZ. The earliest in FDA's data is P990033, decided Oct 25, 1999.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.